Stocktoria
Monte Rosa Therapeutics, Inc. GLUE
Monte Rosa Therapeutics, Inc. (GLUE) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $123.7M at a -31.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.733 |
| Retained earnings / assets | -1.064 |
| EBIT / assets | -0.121 |
| Equity / liabilities | 1.081 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
| IPSC | Century Therapeutics, Inc. | 3/9 | -6.53 | — | — |
| STRO | SUTRO BIOPHARMA, INC. | 2/9 | — | — | +65.2% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
FAQ
Is GLUE financially healthy?
Monte Rosa Therapeutics, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does GLUE pay a dividend?
No, Monte Rosa Therapeutics, Inc. does not currently pay a dividend.
How profitable is GLUE?
In FY2025, Monte Rosa Therapeutics, Inc. had a net margin of -31.2% and a return on equity of -16.6%.
What is the analyst price target for GLUE?
The average Wall-Street price target for Monte Rosa Therapeutics, Inc. is $32.33, about 102.7% above the recent price, from 6 analysts.
Is GLUE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Monte Rosa Therapeutics, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.